Your AI-Trained Oncology Knowledge Connection!
The phase 3 NEPTUNE study indicated that durvalumab plus tremelimumab did not reach an amended primary end point of improved overall survival among patients with metastatic non–small cell lung cancer with a blood tumor mutational burden of at least 20 mut/Mb, though the combination did yield a numerical reduction in risk of death.
Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.
“You have to be on your game continually, you have to continually self-evaluate, and the field moves quickly.”
Data from the phase 1/2 CodeBreaK 100 trial indicated that 84% of patients with KRAS G12C-mutated pancreatic cancer treated with sotorasib experienced disease control.
An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.
Durvalumab plus tremelimumab has been recommended for approval in the European Union for treatment of advanced liver and lung cancers.
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
Topline results from the phase 3 GLOW trial indicated that zolbetuximab plus CAPOX yielded a statistically significant increase in progression-free survival over placebo/CAPOX.
The study’s lead author explained that using rezafungin may avoid some of the negative drug interactions associated with other anti-fungal drugs in patients with cancer.
Data presented at this year’s American Society of Hematology Annual Meeting spotlight promising novel treatment options for acute myeloid leukemia, according to an expert from The University of Texas MD Anderson Cancer Center.
An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
Findings from the phase 3 NORA study identified a numerically longer median overall survival among patients with platinum-sensitive recurrent ovarian cancer treated with maintenance niraparib regardless of BRCA mutation status.
18F-sodium fluoride PET-CT appeared to be a more accurate identifier of bone metastases in patients with breast and prostate cancer than the standard SPECT method.
Future research must address ways to improve the prediction of kidney cancer recurrence to better inform patients, says an expert from the Royal Free London NHS Foundation Trust.
Data from the phase 3 PEARL trial indicated that durvalumab yielded a clinically significant improvement in overall survival but did not meet statistical significance among patients with stage IV non–small cell lung cancer with high PD-L1 expression.
Positive topline data from the phase 2b HERIZON-BTC-01 trial indicate zanidatamab may improve outcomes for patients with HER2-amplified and expressing biliary tract cancers.
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Olaparib in combination with abiraterone and prednisone or prednisolone alone has been approved as treatment for metastatic castration-resistant prostate cancer in the European Union.
Treatment with the BTK inhibitor ibrutinib plus the CAR-T cell therapy tisagenlecleucel produced a high rate of durable responses in patients with relapsed/refractory mantle cell lymphoma after they stopped treatment at 6 months, according to early data from the TARMAC trial.
A panel of experts from Mount Sinai examines representative patient cases and reviews treatments in multiple myeloma.
Kendra Sweet, MD, discussed several ongoing studies in chronic myeloid leukemia, with some initial results presented at the 2022 American Society of Hematology Annual Meeting and Exposition.
Elle Charnisky, a patient with stage IV HER2+ metastatic colorectal cancer (mCRC), joins a panel of healthcare professionals to discuss how HER2 alternations are detected and how patients with HER2+ mCRC are optimally treated to improve outcomes.
Judy C. Boughey, MD; Robert Mutter, MD; and Siddhartha Yadav, MD, MBBS, of Mayo Clinic spoke with CancerNetwork® multidisciplinary findings presented at the 2022 San Antonio Breast Cancer Symposium, ranging from surgery to radiotherapy to biomarker research.
An expert from the University of Texas Southwestern Medical Center questions how providers are currently utilizing stereotactic radiation in the treatment of metastatic kidney cancer.
Bradford S. Hoppe, MD, MPH, and Omran Saifi, MD, offer a peer perspective on research by Gavin Jones, MD, and colleagues into radiation therapy in diffuse large B-cell lymphoma.
Patients with kidney cancer should be made aware of trials that have not read out positively in the adjuvant setting, according to an expert from the Royal Free London NHS Foundation Trust.
Experts present patient cases of those with transplant-eligible or ineligible multiple myeloma and discuss the current standard of care treatment, and how to apply it to their patients.
Kendra Sweet, MD, examined how the data surrounding asciminib in chronic myeloid leukemia will affect the standard of care treatment options.
Acalabrutinib produced promising response rates in combination with lenalidomide and rituximab in previously untreated patients with mantle cell lymphoma.
